Profile data is unavailable for this security.
About the company
Vaccinex, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders. Its lead product candidate, pepinemab, is in clinical development for the treatment of Alzheimer’s disease, head and neck, pancreatic and breast cancer. Its lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop pepinemab for the treatment of various diseases and conditions, including cancer. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.
- Revenue in USD (TTM)124.00k
- Net income in USD-19.19m
- Incorporated2001
- Employees37.00
- LocationVaccinex Inc1895 Mount Hope AveROCHESTER 14620-4540United StatesUSA
- Phone+1 (585) 271-2700
- Fax+1 (585) 271-2765
- Websitehttps://www.vaccinex.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaxxinity Inc | 0.00 | -56.94m | 9.93m | 57.00 | -- | 0.7401 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -16.31m | 10.04m | 5.00 | -- | 2.26 | -- | -- | -0.5804 | -0.5804 | 0.00 | 0.1197 | 0.00 | -- | -- | 0.00 | -212.70 | -36.90 | -378.58 | -37.81 | -- | -- | -- | -- | -- | -- | 0.349 | -- | -- | -- | 43.40 | -- | -- | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 10.04m | -- | -- | -- | 6.63 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Eterna Therapeutics Inc | 115.00k | -22.92m | 10.28m | 8.00 | -- | -- | -- | 89.39 | -4.25 | -4.25 | 0.0214 | -0.6307 | 0.0036 | -- | 0.2305 | 14,375.00 | -70.71 | -169.05 | -88.77 | -223.00 | -114.78 | -- | -19,912.17 | -682.61 | -- | -15.55 | 1.64 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Universe Pharmaceuticals Inc | 32.31m | -6.16m | 10.66m | 225.00 | -- | 0.268 | -- | 0.3299 | -1.70 | -1.70 | 8.91 | 10.91 | 0.5727 | 7.93 | 2.50 | 143,594.40 | -10.92 | 5.31 | -14.34 | 7.07 | 31.93 | 46.26 | -19.08 | 6.25 | 2.43 | -28.05 | 0.1218 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
| Monopar Therapeutics Inc | 0.00 | -7.61m | 10.68m | 10.00 | -- | 1.43 | -- | -- | -0.5289 | -0.5289 | 0.00 | 0.4277 | 0.00 | -- | -- | 0.00 | -73.36 | -54.07 | -92.67 | -60.60 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.10 | -- | -- | -- |
| Scorpius Holdings Inc | 9.74m | -32.20m | 10.73m | 82.00 | -- | 0.1399 | -- | 1.10 | -1.22 | -1.40 | 0.3663 | 0.7937 | 0.1372 | -- | 26.56 | 118,815.70 | -47.81 | -39.37 | -58.20 | -43.18 | 68.56 | -- | -348.43 | -1,068.21 | 0.2641 | -198.18 | 0.3179 | -- | 1,789.58 | 3.84 | 1.96 | -- | 27.32 | -- |
| Vaccinex Inc | 124.00k | -19.19m | 10.74m | 37.00 | -- | 7.57 | -- | 86.63 | -46.02 | -46.02 | 0.1685 | 1.68 | 0.0202 | -- | 0.0894 | 3,351.35 | -312.93 | -262.29 | -731.45 | -- | -- | -- | -15,472.58 | -4,257.17 | -- | -55.90 | 0.03 | -- | 107.27 | -4.67 | -2.20 | -- | -22.20 | -- |
| Medical Marijuana Inc | -100.00bn | -100.00bn | 10.80m | -- | -- | 0.0999 | -- | -- | -- | -- | -- | 0.019 | -- | -- | -- | -- | -- | -22.66 | -- | -23.11 | -- | 70.58 | -- | -145.52 | 1.79 | -- | 0.0479 | -- | 26.30 | 39.07 | 141.59 | -- | -0.016 | -- |
| Allarity Therapeutics Inc | 0.00 | -20.94m | 10.85m | 5.00 | -- | -- | -- | -- | -599.34 | -599.34 | 0.00 | -18.88 | 0.00 | -- | -- | 0.00 | -100.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02 | -- | -- | -- |
| Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 10.91m | 20.00 | -- | -- | -- | 839.55 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
| Bon Natural Life Ltd | 29.52m | 4.60m | 10.92m | 96.00 | 0.5511 | 0.091 | 1.98 | 0.3699 | 4.99 | 4.99 | 32.10 | 30.23 | 0.7045 | 15.27 | 5.19 | 307,524.60 | 10.86 | 14.04 | 13.69 | 20.68 | 29.94 | 30.00 | 15.42 | 17.62 | 2.41 | 30.54 | 0.0955 | 0.00 | -1.29 | 22.32 | -26.32 | 83.09 | -6.70 | -- |
| Moleculin Biotech Inc | 0.00 | -26.82m | 11.03m | 18.00 | -- | 0.5108 | -- | -- | -12.94 | -12.94 | 0.00 | 9.34 | 0.00 | -- | -- | 0.00 | -65.50 | -46.84 | -75.07 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| CV Sciences Inc | 15.86m | -3.23m | 11.10m | 42.00 | -- | 4.70 | -- | 0.6999 | -0.0207 | -0.0207 | 0.1012 | 0.0145 | 1.59 | 1.42 | 27.25 | 377,571.40 | -32.43 | -43.42 | -83.71 | -77.75 | 45.13 | 51.81 | -20.38 | -45.68 | 0.2677 | -13.32 | 0.0472 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
Data as of May 31 2024. Currency figures normalised to Vaccinex Inc's reporting currency: US Dollar USD
22.64%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Mar 2024 | 145.00k | 10.18% |
| Point72 Asset Management LPas of 31 Mar 2024 | 116.55k | 8.18% |
| AIGH Capital Management LLCas of 31 Mar 2024 | 58.37k | 4.10% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 1.11k | 0.08% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.05k | 0.07% |
| Tacita Capital, Inc.as of 31 Mar 2024 | 228.00 | 0.02% |
| UBS Securities LLCas of 31 Mar 2024 | 101.00 | 0.01% |
| Group One Trading LPas of 31 Mar 2024 | 67.00 | 0.01% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Mar 2024 | 53.00 | 0.00% |
| RBC Dominion Securities, Inc. (Investment Management)as of 31 Mar 2024 | 37.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
